China biotech momentum
The Wall Street Journal is highlighting that Chinese biotech companies are advancing faster and at lower cost than many Western peers — a shift that could change where new drugs and trials originate. The WSJ post circulated widely on social (shared with 464 likes and seen by about 67K), which shows the business and public-interest angle is getting traction. (x.com)
Drug companies used to go to China mainly for manufacturing. In 2025 and 2026, more of them started going there for the drug itself. (bmj.com) That means a medicine can now be discovered by a Chinese biotech, tested first in Chinese patients, and then licensed to a Western company that sells it outside China. Pfizer did exactly that in May 2025 when it licensed 3SBio’s cancer drug SSGJ-707 for $1.25 billion upfront, with up to $4.8 billion more in milestones. (pfizer.com) This shift is showing up in the trial numbers too. The British Medical Journal said World Health Organization data show that from January 2024 to June 2025, China accounted for 24% of newly registered clinical trials, ahead of the United States at 20%. (bmj.com) A clinical trial is the stage where a drug is tested in real patients, and speed matters because every extra month burns cash. Nature Biotechnology wrote in January 2026 that rising global drug-development costs are pushing companies to rethink where they launch early human studies. (nature.com) China’s edge is not one magic lab. It is a system built from big hospitals, large patient pools, and regulators that have been trying to shorten review times for studies, according to Nature Biotechnology’s January 2026 overview. (nature.com) That system can move a drug from idea to first patient faster, which makes a half-finished drug more valuable. Nature Biotechnology cited GlobalData saying large-pharma drug licensing from China reached a record 28% in 2024. (nature.com) One reason Western executives are paying attention is that some China-originated drugs are no longer backup options. Summit Therapeutics built one of its biggest cancer bets around ivonescimab, a drug invented by Akeso in China and licensed for the United States, Europe, Japan, Latin America, the Middle East, Africa, and Canada. (smmttx.com) Ivonescimab is a two-in-one antibody, which means one engineered protein tries to hit two cancer pathways at once instead of one. Summit says Akeso’s drug combines a programmed cell death protein 1 blocker with a vascular endothelial growth factor blocker in a single molecule. (smmttx.com) Big drugmakers are responding with money, not just praise. AstraZeneca said on January 29, 2026 that it plans to invest $15 billion in China through 2030 across research, development, and manufacturing, and it named Chinese biotech partners including AbelZeta, CSPC, Harbour BioMed, Jacobio, and Syneron Bio. (astrazeneca.com) The old map of the industry had Boston, Basel, and San Diego inventing drugs while China helped make them cheaply. The new map looks more like China generating more of the molecules, the data, and the early trials, while Western companies increasingly pay for rights to take those drugs global. (bmj.com)
